A new heart drug, designed to combat inflammation, has failed in clinical trials, raising significant doubts about a long-held theory that inflammation is a primary driver of heart disease.

The drug, developed by Novartis, was intended to reduce the risk of heart attacks and strokes by targeting inflammatory processes believed to contribute to atherosclerosis, the hardening and narrowing of arteries.

However, the REDUCE-IT trial, a large-scale study involving thousands of participants, revealed that the drug did not significantly reduce cardiovascular events compared to a placebo. This outcome has sent shockwaves through the medical community, prompting a re-evaluation of the role of inflammation in cardiovascular pathology.

Experts are now debating whether the current understanding of heart disease causation needs a fundamental revision. The failure challenges decades of research and clinical practice that have focused on anti-inflammatory strategies for heart disease prevention and treatment. Further research is needed to explore alternative pathways and develop new therapeutic approaches.